Physician and Industry Groups to Discuss Sunshine Act Implementation
WASHINGTON, D.C. — The American Association of Neurological Surgeons (AANS) and the Pharmaceutical Research and Manufacturers of America (PhRMA) will host a conference call highlighting a letter that 25 physician associations and biopharmaceutical and medical technology groups are sending to CMS about the Physician Payments Sunshine Act. Representatives will be available to discuss the contents of the letter, which includes the need for context once the Sunshine data is released and a request to simplify physician registration.
As the deadline for the database release draws closer, concern is increasing about lack of physician awareness, a cumbersome registration process, and lack of information of how the data will be presented. To date, the physician and biopharmaceutical and medical technology communities have not received any information as to how the data with be conveyed. Ensuring that the information is provided with appropriate background is critical to helping the public understand various interactions and ensuring that the interactions are not misconstrued.
WHO: Robert E. Harbaugh, MD, FAANS, President
American Association of Neurological Surgeons
John Murphy, JD, Assistant General Counsel
WHAT: Media call to discuss collaborative physician-industry letter to CMS regarding the Physician Payments Sunshine Act
WHEN: Tuesday, July 29, 2014 at 11:30 a.m. EST
About the American Association of Neurological Surgeons
Founded in 1931 as the Harvey Cushing Society, the American Association of Neurological Surgeons (AANS) is a scientific and educational association with over 8,000 members worldwide. The AANS is dedicated to advancing the specialty of neurological surgery in order to provide the highest quality of neurosurgical care to the public. Neurosurgery is the medical specialty concerned with the prevention, diagnosis, treatment and rehabilitation of disorders that affect the spinal column, spinal cord, brain, nervous system and peripheral nerves. For more information, please visit www.aans.org, read our blog www.neurosurgeryblog.org, follow us on Twitter or connect with us on Facebook.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.